Singapore markets closed
  • Straits Times Index

    3,245.97
    +9.89 (+0.31%)
     
  • Nikkei

    27,901.01
    +326.58 (+1.18%)
     
  • Hang Seng

    19,900.87
    +450.64 (+2.32%)
     
  • FTSE 100

    7,476.63
    +4.46 (+0.06%)
     
  • BTC-USD

    17,150.47
    -96.69 (-0.56%)
     
  • CMC Crypto 200

    402.11
    -4.14 (-1.02%)
     
  • S&P 500

    3,934.38
    -29.13 (-0.73%)
     
  • Dow

    33,476.46
    -305.02 (-0.90%)
     
  • Nasdaq

    11,004.62
    -77.39 (-0.70%)
     
  • Gold

    1,809.40
    +7.90 (+0.44%)
     
  • Crude Oil

    71.59
    +0.13 (+0.18%)
     
  • 10-Yr Bond

    3.5670
    +0.0760 (+2.18%)
     
  • FTSE Bursa Malaysia

    1,477.19
    +11.26 (+0.77%)
     
  • Jakarta Composite Index

    6,715.12
    -89.11 (-1.31%)
     
  • PSE Index

    6,580.12
    +54.96 (+0.84%)
     

AMILI raises US$10.5 million Series A round led by Vulcan Capital

AMILI’s Series A funding round aims to accelerate the company’s business expansion in Southeast Asia and wider Asia subsequently.

AMILI, Singapore-based precision gut microbiome company, announced today that it has raised US$10.5 million in its Series A round.

The funding round was led by Vulcan Capital, with new investors including Pruksa Group, TVM Capital Healthcare, Emtek Group, Capital Code and SEEDS Capital, the investment arm of Enterprise Singapore amongst others.

AMILI’s Series A funding round aims to accelerate the company’s business expansion in Southeast Asia and wider Asia subsequently.

“Although gut health research has advanced steadily over the years in other regions, there is still a big gap in research that is representative of the Asian population,” says Tommy Teo, managing director of Vulcan Capital. “We are excited to journey with AMILI as it advances microbiome research and positively impacts millions of lives.”

AMILI is a precision gut health company building the world’s largest multi-ethnic Asia-centric microbiome repository of data and samples, including Southeast Asia’s only microbiome bank. AMILI through its proprietary analytics engine, AMILI PRIME, develops diagnostics tests, predictive algorithms and microbiome-modifying interventions.

AMILI has three core assets which allows it to create and capture value– firstly, a multi-ethnic Asia microbiome database, secondly, a microbiome bank with samples stored for metagenomic and metabolomic analysis, and lastly, AMILI PRIME, a set of proprietary analytical tools, informatics pipelines and discovery engines.

The core assets are used to support AMILI’s four commercial engines in the areas of diagnostics and therapeutics, faecal microbiota transplants (FMT), personalised wellness and ‘food for health’.

At present, AMILI is the only FMT provider in Southeast Asia, serving the region’s 680 million people. It houses Southeast Asia’s first and only gut microbiome bank for clinical use and research as well.

AMILI also recently launched its direct-to-consumer precision gut health brand, BIO & ME, in Singapore and plans to expand into the rest of Southeast Asia and Hong Kong later this year.

The company also has several partnerships ranging from large fortune 500 MNCs to insurgent brands in the consumer space and continues to break new ground in this area.

See Also: